{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:07:23Z","timestamp":1789628843358,"version":"build-2803163510"},"reference-count":14,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades infecciosas y microbiologia clinica (English ed.)"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.eimce.2022.06.017","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T18:09:17Z","timestamp":1674670157000},"page":"567-570","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["In vitro activity of ceftobiprole and dalbavancin against a collection of coagulase-negative staphylococci isolates from clinical samples with reduced susceptibility to daptomycin and\/or resistant to linezolid or glycopeptides"],"prefix":"10.1016","volume":"41","author":[{"given":"Silvia","family":"Velasco de la Fuente","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Fern\u00e1ndez-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Rodr\u00edguez Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Pablo-Marcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Siller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimce.2022.06.017_bib0075","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1080\/14787210.2019.1667229","article-title":"Ceftobiprole: drug evaluation and place in therapy","volume":"17","author":"Giacobbe","year":"2019","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"Suppl. 3","key":"10.1016\/j.eimce.2022.06.017_bib0080","first-page":"3","article-title":"Mechanisms of action and antimicrobial activity of ceftobiprole","volume":"32","author":"Morosini","year":"2019","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.eimce.2022.06.017_bib0085","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.medcli.2019.11.002","article-title":"Nuevos antibi\u00f3ticos para el tratamiento de las infecciones por microorganismos multirresistentes","volume":"154","author":"Escol\u00e0-Verg\u00e9","year":"2020","journal-title":"Med Clin (Barc)"},{"issue":"Suppl. 1","key":"10.1016\/j.eimce.2022.06.017_bib0090","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0213-005X(17)30029-0","article-title":"Espectro antimicrobiano de dalbavancina. Mecanismo de acci\u00f3n y actividad in vitro frente a microorganismos Gram-positivos","volume":"35","author":"Cercenado","year":"2017","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimce.2022.06.017_bib0095","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13756-020-00714-9","article-title":"The global prevalence of daptomycin, tigecycline, quinupristin\/dalfopristin, and linezolid-resistant Staphylococcus aureus and coagulase-negative staphylococci strains: a systematic review and meta-analysis","volume":"9","author":"Shariati","year":"2020","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.eimce.2022.06.017_bib0100","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0, 2021. Available from: http:\/\/www.eucast.org."},{"key":"10.1016\/j.eimce.2022.06.017_bib0105","unstructured":"Clinical and Laboratory Standards Institute. (CLSI). Performance Standards for Antimicrobial Susceptibility Testing, 28th ed.; M100; CLSI: Wayne, PA, USA, 2021."},{"key":"10.1016\/j.eimce.2022.06.017_bib0110","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s10096-018-3295-6","article-title":"Comparative activity of ceftobiprole against coagulase-negative staphylococci from the BSAC Bacteraemia Surveillance Programme, 2013\u20132015","volume":"37","author":"Henriksen","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.eimce.2022.06.017_bib0115","first-page":"e01566","article-title":"Ceftobiprole activity against Gram-positive and -negative pathogens collected from the United States in 2006 and 2016","volume":"63","author":"Pfaller","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimce.2022.06.017_bib0120","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1128\/AAC.02465-14","article-title":"Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010","volume":"58","author":"Farrell","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimce.2022.06.017_bib0125","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.diagmicrobio.2017.12.020","article-title":"Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015)","volume":"91","author":"Pfaller","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.eimce.2022.06.017_bib0130","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jgar.2020.11.020","article-title":"Antimicrobial activity of dalbavancin against clinical isolates of coagulase-negative staphylococci from the USA and Europe stratified by species","volume":"24","author":"Sader","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.eimce.2022.06.017_bib0135","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.diagmicrobio.2005.03.004","article-title":"Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens","volume":"53","author":"Streit","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.eimce.2022.06.017_bib0140","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1093\/jac\/dky235","article-title":"Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015\u201316","volume":"73","author":"Pfaller","year":"2018","journal-title":"J Antimicrob Chemother"}],"container-title":["Enfermedades infecciosas y microbiologia clinica (English ed.)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2529993X23000199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2529993X23000199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:03:42Z","timestamp":1762866222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2529993X23000199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2529993X23000199"],"URL":"https:\/\/doi.org\/10.1016\/j.eimce.2022.06.017","relation":{},"ISSN":["2529-993X"],"issn-type":[{"value":"2529-993X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of ceftobiprole and dalbavancin against a collection of coagulase-negative staphylococci isolates from clinical samples with reduced susceptibility to daptomycin and\/or resistant to linezolid or glycopeptides","name":"articletitle","label":"Article Title"},{"value":"Enfermedades infecciosas y microbiologia clinica (English ed.)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimce.2022.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}